Madison's Third Wave Technologies has won another round in its patent fight with Digene Corp. The latest ruling by the U.S. District Court in Western Wisconsin makes it more likely that Third Wave will prevail in the lawsuit, which Digene has filed in relation to...
The new rules of eDiscovery require more thought and action than simply turning off the office shredder. In this fourth and final part of WTN's series on electronic document retention, attorney Joe Olson addresses the how and when of eDiscovery, including effective litigation hold -...
For anyone interested in open source software but operating under the assumption that it's "free," attorney and columnist Deborah Wilcox has some upsetting news. In this edition of IP Online, she explains why open source is anyting but free, and she advises companies to develop...
There is more than one way to finance a start-up technology or biotechnology company, according to columnist and Madison attorney Joe Boucher. In this 12th edition of Early Stage, he looks at still more alternative forms of business finance, including factoring receivables and sales and...
With eDiscovery, the benefits of a written document retention policy and a formal review process are many, according to Michael Best & Friedrich attorney John Flanagan. In this third in a four-part series on e-discovery, a new mandate that companies are struggling with, Flanagan explains...
Ever wonder why so many people can't find good-paying jobs in IT and other fields? In this edition of Carlini's Comments, James Carlini charges that some American employers are selling out their country by shutting qualified Americans out of the hiring process in favor of...
Early-stage companies can benefit from having an Advisory Board of people who have “been there and done that,” but the trick is using their expertise effectively. In this guest column on building a team of advisors, Michael Best and Friedrich attorney William Robinson shares some...
When it comes to approving drugs in the United States, should safety be the primary endpoint for approval? In this second part of a MedTech Futures column on the FDA approval process, Dr. Ogan Gurel calls for the FDA to refocus its primary mission on...
The recent controversy over GlaxoSmithKline's diabetes drug Avandia has once again put the Food & Drug Administration in Congressional crosshairs. In Part I of a MedTech Futures column on the FDA approval process, Dr. Ogan Gurel suggests that safety-minded FDA employees be taken more seriously. ...
When it comes to managing e-documents, there is a legal recognition that sometimes they have to be destroyed, notes Michael Best & Friedrich attorney Juan Ramirez. As he explains in this second guest column on e-discovery, there is limited safe harbor protection in the event...